dexamethasone + dexmedetomidine + levobupivacaine

This is a combination of three drugs—dexamethasone, dexmedetomidine, and levobupivacaine—used primarily as an adjuvant mixture for regional anesthesia and perioperative pain management. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties. It prolongs analgesia when used as an adjunct in nerve blocks, likely through vasoconstriction (reducing local anesthetic absorption), inhibition of potassium channels on nociceptive C-fibers, and suppression of inflammatory responses both peripherally and centrally[4]. - **Dexmedetomidine** is a highly selective alpha-2 adrenergic receptor agonist that provides sedative, anxiolytic, and analgesic effects without significant respiratory depression. Its analgesic effect in nerve blocks is mediated by binding to alpha-2 receptors in the central nervous system, inhibiting the release of nociceptive neurotransmitters[4][9]. - **Levobupivacaine** is the S(-)-enantiomer of bupivacaine; it acts as a long-acting local anesthetic by blocking neuronal voltage-gated sodium channels to prevent nerve impulse transmission[6][8]. It has lower cardiotoxicity than racemic bupivacaine. When combined for peripheral or neuraxial nerve block procedures (e.g., interscalene block), this mixture has been shown to synergistically prolong the duration of sensory blockade and postoperative analgesia compared to single agents or placebo[1][3][7]. The combination may also reduce opioid requirements postoperatively. The safety profile appears acceptable based on current studies; however, caution should be exercised in patients with pre-existing heart disease due to potential cardiovascular effects from dexmedetomidine[4].